The report NK Cell Therapeutics assesses the global market based upon application, end-user, and region. The report includes trend analysis and historical market data. The report includes market share analysis, production capabilities by top players, competition overview, and strategic imperatives. It also highlights annual sales figures, growth avenues, and clinical trial phases.
Market Overview & Dynamics: The market growth is being driven by the ongoing clinical and pre-clinical development of NK-cell-based therapies.
Global NK cell therapeutics markets are expected to expand at a strong CAGR of more than 50% over the forecast period 2022-2028. NK cells have been shown to be effective in a variety of molecular and combinational therapies, which has increased their acceptance for treatment. NK cells are being used by scientists and healthcare professionals as an anti-cancer tool and an effective tool in fighting infectious diseases. This has accelerated the clinical development and commercialization of NK-cell-based therapies, which are key growth factors in the global market.
There is a growing need to develop novel treatments for cancer due to its increasing prevalence. The NK cells play a crucial role in tumor immune surveillance. This further encourages the adoption of NK cell-based therapies worldwide. Market growth is being accelerated by the increasing use of NK cell-based therapies in the treatment of cancer and other diseases. Market growth is expected to be further accelerated by the increasing awareness of immunotherapies among patients.
Together, North America and Europe are expected to generate substantial revenue due to increased R&D efforts by market leaders in developing novel treatments for cancer treatment. Market players are involved in the development of NK-cell-based therapies to treat various diseases, including cancer. Recent submissions of a large number of clinical trial applications for NK-cell therapeutics indicate a promising future.
Segmental Analysis
• The application segment will hold a significant share of the market due to the rising prevalence of cancer worldwide and the increased demand for new treatments.
• The fastest growing segment on the basis of end-users is the research center and institutes segment. This is due to the increasing R&D efforts in drug and treatment development.
• Due to the high level of investment made by industry leaders in the development and commercialization of NK-cell-based therapies, North America will dominate the global NK cells therapeutics market.

Competition Analysis: Significant market consolidation is expected in the near future
The global NK cell therapeutics market is at a nascent stage and is expected to flourish in the upcoming years. Players involved in the research & development of NK cell-based therapies are heavily investing in the sector with a keen focus on oncology treatment. Product innovations, launches, partnerships, mergers & acquisitions are the identified industry trends in the global NK cell therapeutics market. For instance,
• In August 2022, Zelluna Immunotherapy announced an investment from Takeda Ventures, Inc. (TVI), the strategic investing arm of Takeda. TVI investment joins Zelluna's latest financing round. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and, continue the advancement of Zelluna's platform with additional programs reaching the preclinical stage.
• In January 2022, Takeda announced to acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors. Through the acquisition, Takeda would obtain Adaptate's antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate's γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumor sites while sparing damage to healthy cells.
Some of the leading players involved in the research & development, production, and marketing of NK cell therapeutics include Nkarta, Inc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Affimed GmbH, Zelluna Immunotherapy, Nektar Therapeutics, XNK Therapeutics AB, ONK Therapeutics, Catarman Bio, MiNK Therapeutics, Celularity Inc., Artiva Biotherapeutics and others.
RationalStat has segmented the Global NK Cell Therapeutics Market on the basis of application, end user, and region.
• By Application
o Cancer
o Gastrointestinal Diseases
o Immunoproliferative Disorders
o Others
• By End User
o Hospitals
o Research Centers and Institutes
o Others
• By Region
o North America
 US
 Canada
o Latin America
 Brazil
 Mexico
 Rest of Latin America
o Western Europe
 Germany
 UK
 France
 Spain
 Italy
 Benelux
 Nordic
 Rest of Western Europe
o Eastern Europe
 Russia
 Poland
 Rest of Eastern Europe
o Asia Pacific
 China
 Japan
 India
 South Korea
 Australia
 ASEAN (Indonesia, Vietnam, Malaysia, etc.)
 Rest of Asia Pacific
o Middle East & Africa
 GCC
 South Africa
 Turkey
 Rest of the Middle East & Africa

For more information about this report https://store.rationalstat.com/store/global-natural-killer-nk-cell-therapeutics-market-investment-growth-opportunity-analysis/
About RationalStat LLC
RationalStat is an end-to-end US-based market intelligence and consulting company that provides comprehensive market research reports along with customized strategy and consulting studies. The company has sales offices in India, Mexico, and the US to support global and diversified businesses. The company has over 80 consultants and industry experts, developing more than 850 market research and industry reports for its report store annually.
RationalStat has strategic partnerships with leading data analytics and consumer research companies to cater to the client’s needs. Additional services offered by the company include consumer research, country reports, risk reports, procurement intelligence, data analytics, and analytical dashboards.
Contact
RationalStat LLC
Kimberly Shaw, Content and Press Manager
[email protected]
Phone: +1 302 803 5429